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Abstract
A series of pyrrolo[2,3-d]pyridazinones was synthesized and tested for their inhibitory activity on PDE4 subtypes A, B and D
and selectivity toward Rolipram high affinity binding site (HARBS). New agents with interesting profile were reported; in
particular compound 9e showed a good PDE4 subtype selectivity, being 8 times more potent (IC50 ¼ 0.32mM) for PDE4B
(anti-inflammatory) than for PDE4D (IC50 ¼ 2.5mM), generally considered the subtype responsible for emesis. Moreover
the ratio HARBS/PDE4B was particularly favourable for 9e (147), suggesting that the best arranged groups around the
pyrrolopyridazinone core are an isopropyl at position-1, an ethoxycarbonyl at position-2, together with an ethyl group at
position-6.
For compounds 8 and 15a the ability to inhibit TNFa production in PBMC was evaluated and the results are consistent
with their PDE4 inhibitory activity.
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Introduction
Phosphodiesterases (PDEs), are the enzymes respon-
sible for the hydrolysis of cyclic adenosine monophos-
phate (c-AMP) and cyclic guanosine monophosphate
(c-GMP) which play a key role as secondary
messengers in cell functions. The PDE4 subfamily,
specific for cAMP, is identified by four subtypes
(PDE4A, PDE4B, PDE4C and PDE4D). Each
subtype is differently expressed in various tissues, in
particular PDE4A and PDE4B isoforms are ubiqui-
tous, while PDE4C and PDE4D are essentially
present in neuronal tissue and in inflammatory cells
respectively[1,2]. In the last few years PDE4 has
attracted considerable interest as a therapeutic target
for a variety of pathologies, such as asthma, chronic
obstructive pulmonary diseases (COPD) and inflam-
matory diseases[3]. Since recent studies demonstrated
the fundamental role of inflammation in asthma
pathology[4,5], it is clear that selective PDE4
inhibitors which are able to both suppress inflamma-
tory progression and to reduce the bronchial smooth
muscle tone, represent a very attractive alternative to
the classic combined therapy with corticosteroids and
bronchodilators. New important applications of PDE4
inhibitors have been proposed, such as in rheumatoid
arthritis and other important autoimmune diseases,
this hypothesis being associated with the evidence that
PDE4 selective inhibitors strongly reduce tumor
necrosis factor a (TNF-a) production which plays an
important role in these types of pathologies[6]. Recent
studies demonstrated an increase of PDE catalytic
activity together with an increase of sensitivity to
PDE4 inhibitors in atopic dermatitis, suggesting that
this pathology could be an attractive target for PDE4
inhibitors[7,8]. Finally, the presence of differently
located subtypes of PDE4 opens new opportunities for
the development of selective inhibitors devoid of
limiting side-effects[9].
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The archetypal PDE4 inhibitor Rolipram 1[10]
(Figure 1) showed very important unwanted side-
effects, such as headache, nausea and vomiting, which
are related to the binding of 1 with Rolipram high
affinity binding site (HARBS)[11]. This same effect
was found in Rolipram analogues and in many other
compounds structurally unrelated to Rolipram, such
as quinazolinediones 2 and xanthine derivatives
3[12–14].
Thus it appears very important to dissociate the
affinity for HARBS from PDE4 inhibitory activity, in
order to obtain more selective antiasthmatic drugs,
devoid of the above side-effects. In recent years, potent
and selective PDE4 inhibitors with reduced affinity for
HARBS have been described in the literature[15] and
a number of these are now in clinical trials.
Compounds such as Cilomilast 4[16,17], Roflumilast
5[18,19], CDP-840 6[20] or YM-976 7[21] are well
tolerated and are presently in phase III clinical trials for
the treatment of asthma and COPD (compounds 4
and 5)[22–24] and in phase II clinical trials for
asthmatic pathology (compounds 6 and 7)[25–27].
Roflumilast and CDP-840 didn’t demonstrate
PDE4 subtype selectivity[7,19], whereas Cilomilast is
10-fold more selective for PDE4D than for PDE4A
and PDE4B[28]. Presently some compounds with high
selectivity for one PDE4 subtype (up to 300-fold) have
been synthesized, and recent studies demonstrated a
correlation between PDE4A/B inhibitory activity and
TNFa release inhibition[7]. Moreover some authors
suggested that PDE4D is the subtype responsible for
the emetic side-effects[29]. These results and proposals
seems to open new opportunities for the development
of selective inhibitors with reduced adverse effects.
Figure 1. PDE4 inhibitors.
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A systematic screening performed on our internal
library, allowed us to identify compound 8 as an
interesting lead. This compound exhibited IC50 in the
same micromolar range as Rolipram (IC50 ¼ 0.6mM)
and a good selectivity profile versus PDE4
(PDE3/PDE4 . 30). Moreover it displays low
affinity for HARBS (IC50 ¼ 2.0mM). Thus it pos-
sesses a much better ratio of PDE4 inhibitory activity
versus affinity for HARBS (HARBS/PDE4 ¼ 3.33 for
9, and 0.02 for Rolipram).
On this basis we report here some chemical
modifications of lead compound 8 which afforded
the new pyrrolo[2,3-d]pyridazines 9a–e and 15a–f
and their PDE4 subtypes inhibitory activity.
Materials and methods
All melting points were determined on a Buchi
apparatus and are uncorrected. 1H-NMR spectra were
recorded with Varian Gemini 200 instruments.
Chemical shifts are reported in ppm, using the solvent
as internal standard. Extracts were dried over Na2SO4
and the solvents were removed under reduced
pressure. Merck F-254 commercial plates were used
for analytical TLC to follow the course of the reaction.
Silica gel 60 (Merck 70–230 mesh) was used for
column chromatography.
Chemistry
The synthesis of the novel pyrrolo[2,3-d]pyridazi-
nones 9a–e and 15a–f is depicted in Figures 2 and 3
respectively.
In Figure 2, the procedure affording the N-1
substituted compounds 9a–e is reported. All final
productswere prepared starting from the lead compound
8 which was alkylated under standard conditions to
afford thecorrespondingN-substitutedderivatives9a–e.
In Figure 3, is depicted the synthetic route affording
the pyrrolo[2,3-d]pyridazinones 15a–f in which
modifications at positions- 3, -6 and on the phenyl
ring of the bicyclic system were performed with
respect to the lead 8.
Isoxazoles of type 10, which are the starting material
for the final compounds 15 have been previously
described[30–32] with the exception of 10b. Treat-
ment of isoxazoles 10 with hydrazine followed by
alkylation with the appropriate alkyl halide afforded
compounds 12, which were transformed into the 4-
nitropyridazinone derivatives 13 through oxidative
cleavage of the isoxazole ring[30]. Displacement of the
nitro group with glycine ethyl ester afforded the open
intermediates 14 which led to the final pyrrolopyr-
idazinones 15 by treatment with sodium ethoxide in
absolute ethanol at room temperature (11d[33], 12d–
f [34],13d–f [33]).
General procedure for compounds 9a–e. A suspension of
8 (0.3 mmol), anhydrous K2CO3 (6 mmol) and the
appropriate halide (0.5 mmol) in anhydrous DMF was
heated for 30–60 min (16 h for 9e) at 80–1108C.
After the mixture was cooled, ice cold water was
added and the crude precipitate was recovered by
suction, with the exception of 9d which was extracted
with CH2Cl2 (3 £ 15 mL).
Ethyl 6,7-dihydro-1,3-dimethyl-6-ethyl-7-oxo-4-phe-
nyl-1H-pyrrolo[2,3-d]pyridazine-2-carboxylate 9a.
Mp ¼ 82–838C; crystallization solvent ¼ EtOH;
yield ¼ 45%.
1H-NMR (CDCl3), d, ppm: 1.45 (m, 6H, NCH2CH3
and OCH2CH3), 2.10 (s, 3H, CCH3), 4.35 (m, 4H,
NCH2CH3 and OCH2CH3), 4.50 (s, 3H, NCH3),
7.45 (s, 5H, Ar).
Anal. found: C, 67.40; H, 6.24; N, 12.34.
C19H21N3O3 requires: C, 67.23; H, 6.25; N, 12.38%.
Ethyl 1,6-diethyl-6,7-dihydro-3-methyl-7-oxo-4-phe-
nyl-1H-pyrrolo[2,3-d]pyridazine-2-carboxylate 9b.
Mp ¼ 77–788C; crystallization solvent ¼ EtOH;
yield ¼ 55%.
1H-NMR (CDCl3), d, ppm: 1.40 (m, 9H,
2NCH2CH3 and OCH2CH3), 1.95 (s, 3H, CCH3),
4.35 (m, 4H, NCH2CH3 and OCH2CH3), 5.10
(q, 2H, NCH2CH3), 7.45 (s, 5H, Ar).
Figure 2. Synthesis of pyrrolo[2,3-d]pyridazinones 9a–e.
Selective PDE4 subtype inbibitors 311
Anal. found: C, 68.03; H, 6.58; N, 11.92.
C20H23N3O3 requires: C, 67.96; H, 6.57; N, 11.89%.
Ethyl 6,7-dihydro-6-ethyl-3-methyl-7-oxo-4-phenyl-1-
propyl-1H-pyrrolo[2,3-d]pyridazine-2-carboxylate 9c.
Mp ¼ 77–788C; crystallization solvent ¼ EtOH;
yield ¼ 90%.
1H-NMR (CDCl3), d, ppm: 0.95 (t, 3H, (CH2)2CH3),
1.40 (m, 6H, NCH2CH3 and OCH2CH3), 1.80 (m,
2H, CH2CH2CH3), 1.95 (s, 3H, CCH3), 4.35 (m, 4H,
NCH2CH3 and OCH2CH3), 5.00 (t, 2H, NCH2CH2
CH3), 7.45 (s, 5H, Ar).
Anal. found: C, 68.80; H, 6.89; N, 11.41.
C21H25N3O3 requires: C, 68.63; H, 6.87; N, 11.44%.
Ethyl 1-benzyl-6,7-dihydro-6-ethyl-3-methyl-7-oxo-4-
phenyl-1H-pyrrolo[2,3-d]pyridazine-2-carboxylate 9d.
Mp ¼ 105–1068C; crystallization solvent ¼ EtOH;
yield ¼ 70%.
1H-NMR (CDCl3), d, ppm: 1.25 (t, 3H, NCH2CH3),
1.40 (t, 3H, OCH2CH3), 2.00 (s, 3H, CCH3), 4.30
(m, 4H, NCH2CH3 and OCH2CH3), 6.40 (s, 2H,
NCH2Ph), 7.10 (m, 2H, Ar), 7.25 (m, 3H, Ar), 7.50
(s, 5H, Ar).
Anal. found: C, 72.09; H, 6.09; N, 10.08.
C25H25N3O3 requires: C, 72.26; H, 6.08; N, 10.11%.
Ethyl 6,7-dihydro-6-ethyl-1-isopropyl-3-methyl-7-oxo-
4-phenyl-1H-pyrrolo[2,3-d]pyridazine-2-carboxylate 9e.
Mp ¼ 99–1018C; crystallization solvent ¼ EtOH;
yield ¼ 60%.
1H-NMR (CDCl3), d, ppm: 1.40 (m, 6H, NCH2CH3
and OCH2CH3), 1.70 (d, 6H, CH(CH3)2), 1.85 (s, 3H,
CCH3), 4.35 (m, 4H, NCH2CH3 and OCH2CH3),
5.85 (m, 1H, CH(CH3)2), 7.45 (s, 5H, Ar).
Anal. found: C, 68.79; H, 6.89; N, 11.42.
C21H25N3O3 requires: C, 68.63; H, 6.87; N, 11.44%.
Ethyl-4-benzoyl-5-propylisoxazole-3-carboxylate 10b. To
a cooled (25–108C) and stirred solution of sodium
ethoxide, obtained from sodium (15 mmol) and
anhydrous EtOH (30 mL), a solution of 1-
phenylhexan-1,3-dione[35] (15 mmol) in the same
solvent (15 mL) was slowly added. A solution of ethyl
chloro(hydroximino)acetate, commercially available
(15 mmol) in anhydrous EtOH (10 mL) was added in
a dropwise manner (over 1 h period). The mixture,
neutralized with 6N HCl was evaporated to afford an
oil which was washed with 0.5 N NaOH and water and
then extracted with CH2Cl2 (3 £ 25 mL). The organic
layer was washed with water, dried with Na2SO4 and
evaporated in vacuo to afford an oil, which was purified
by column chromatography (cyclohexane/ethyl acetate
1:1). Yield ¼ 57%.
1H-NMR (CDCl3), d, ppm: 1.00 (t, 6H, 2CH3),
1.80 (m, 2H, CH2CH2CH3), 2.90 (t, 2H, CH2CH2-
CH3), 4.10 (q, 2H, OCH2CH3), 7.50 (s, 5H, Ar).
General procedure for compounds 11a–c. The appropriate
isoxazole 10a–c (0.5 mmol) was dissolved in EtOH
(5mL) and then hydrazine hydrate (0.8 mmol) was
added at room temperature. After 10–60 min the crude
product was collected by suction from the cooled
mixture.
3-Ethyl-4-phenylisoxazolo[3,4-d]pyridazin-7-(6H)-
one 11a. Mp ¼ 204–2068C; crystallization solvent ¼
EtOH; yield ¼ 81%.
1H-NMR (CDCl3), d, ppm: 1.20 (t, 3H, CH3), 2.80
(q, 2H, CH2), 7.50 (s, 5H, Ar).
4-Phenyl-3-n.propylisoxazolo[3,4-d]pyridazin-7-
(6H)-one 11b. Mp ¼ 146–1488C; crystallization
solvent ¼ EtOH; yield ¼ 82%.
1H-NMR (CDCl3), d, ppm: 0.90 (t, 3H, CH3), 1.80
(m, 2H, CH2CH2CH3), 2.80 (t, 2H, CH2CH2CH3),
7.50 (s, 5H, Ar), 10.00 (exch br s, 1H, NH).
Figure 3. Synthesis of pyrrolo[2,3-d]pyridazinones 15a–f.
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4-(p-Chlorophenyl)-3-methylisoxazolo[3,4-d]pyrida-
zin-7-(6H)-one 11c. Mp ¼ 210–2128C; crystalliza-
tion solvent ¼ EtOH; yield ¼ 74%.
1H-NMR (CDCl3), d, ppm: 2.60 (s, 3H, CH3), 7.50
(m, 4H, Ar), 9.90 (exch br s, 1H, NH).
General procedure for compounds 12a–c. A mixture of
the appropriate isoxazolo[3,4-d]pyridazinones 11
(1 mmol), anhydrous K2CO3 (5 mmol) and
appropriate alkyl bromide (5 mmol) in anhydrous
DMF (3–6 mL) was heated under stirring for 1 h at
1108C. After dilution with cold water (80–100 mL)
the crude precipitate was recovered by suction.
3,6-Diethyl-4-phenylisoxazolo[3,4-d]pyridazin-
7(6H)-one 12a. Mp ¼ 67–708C; crystallization
solvent ¼ EtOH; yield ¼ 86%.
1H-NMR (CDCl3), d, ppm: 1.20 (t, 3H, CCH2CH3),
1.40 (t, 3H, NCH2CH3), 2.85 (q, 2H, CCH2CH3),
4.30 (q, 2H, NCH2CH3), 7.55 (s, 5H, Ar).
6-Ethyl-4-phenyl-3-n.propylisoxazolo[3,4-d]pyrida-
zin-7(6H)-one 12b. Mp ¼ 70–728C; crystallization
solvent ¼ EtOH; yield ¼ 75%.
1H-NMR (CDCl3), d, ppm: 0.90 (t, 3H, CH2CH2
CH3), 1.50 (t, 3H, NCH2CH3), 1.80 (m, 2H,
CH2CH2CH3), 2.80 (m, 2H, CH2CH2CH3), 4.25
(m, 2H, NCH2CH3), 7.50 (s, 5H, Ar).
4-(p-Chlorophenyl)-6-ethyl-3-methylisoxazolo[3,4-
d]pyridazin-7(6H)-one 12c. Mp ¼ 126–1288C; crys-
tallization solvent ¼ EtOH; yield ¼ 70%.
1H-NMR (CDCl3), d, ppm: 1.40 (t, 3H, NCH2CH3),
2.50 (s, 3H, CCH3), 4.20 (q, 2H, NCH2CH3), 7.50
(m, 4H, Ar).
General procedure for compounds 13a–c. To a stirred
suspension of the appropriate compounds 12
(2.5 mmol) in AcOH (50% w/v; 20 mL) and HNO3
(65% w/v; 2.5 mL), CAN (15 mmol) was added in a
portionwise manner at 558C over 30–45 min period.
Then ice-cold water (100 mL) was added and
compounds 13a and 13c were recovered by suction;
to obtain 13b the mixture was extracted with CH2Cl2
(3 £ 20 mL). Evaporation of the solvent afforded an
oil which was purified by column chromatography
using toluene/ethyl acetate (8:2) as eluent.
2-Ethyl-4-nitro-6-phenyl-5-propionylpyridazin-
3(2H)-one 13a. Mp ¼ 97–1008C; crystallization
solvent ¼ EtOH; yield ¼ 65%.
1H-NMR (CDCl3), d, ppm: 0.95 (t, 3H, COCH2CH3),
1.50 (t, 3H, NCH2CH3), 2.35 (q, 2H, COCH2CH3),
4.40 (q, 2H, NCH2CH3), 7.50 (s, 5H, Ar).
5-Butyryl-2-ethyl-6-phenyl-4-nitropyridazin-3(2H)-
one 13b. oil; yield ¼ 52%.
1H-NMR (CDCl3), d, ppm: 0.90 (t, 3H, COCH2
CH2CH3), 1.50 (m, 5H, NCH2CH3 and COCH2
CH2CH3), 2.35 (m, 2H, COCH2CH2CH3), 4.40
(q, 2H, NCH2CH3), 7.50 (s, 5H, Ar).
5-Acetyl-6-(p-chlorophenyl)-2-ethyl-4-nitropyridazin-
3(2H)-one 13c. Mp ¼ 105–1078C; crystallization
solvent ¼ EtOH; yield ¼ 59%.
1H-NMR (CDCl3), d, ppm: 1.50 (t, 3H, NCH2CH3),
2.20 (s, 3H, COCH3), 4.40 (q, 2H, NCH2CH3), 7.50
(m, 4H, Ar).
General procedure for compounds 15a–f. A suspension of
the appropriate nitroderivative 13 (0.3 mmol) and
glycine ethyl ester (0.6 mmol) in EtOH (3 mL) was
heated at 40–508C for 20–160 min. After cooling, the
intermediate 14 was recovered by suction. The crude
14, completely dried, was treated with EtONa
(0.5 mmol) in absolute. EtOH (3 mL) at room
temperature for 20–30 min. After dilution with
water (10 mL), the mixture was acidified with 6N
HCl to afford compounds of type 15 which were
recovered by suction.
Ethyl 3,6-diethyl-6,7-dihydro-4-phenyl-7-oxo-1H-pyr-
rolo[2,3-d]pyridazine-2-carboxylate 15a. Mp ¼ 127–
1318C; crystallization solvent ¼ EtOH; yield ¼ 68%.
1H-NMR (CDCl3), d, ppm: 0.80 (t, 3H, CCH2CH3),
1.40 (m, 6H, NCH2CH3 and OCH2CH3), 2.60 (q,
2H, CCH2CH3), 4.35 (m, 4H, NCH2CH3 and
OCH2CH3), 7.50 (m, 4H, Ar).
Anal. found: C, 67.40; H, 6.24; N, 12.40.
C19H21N3O3 requires: C, 67.23; H, 6.25; N, 12.38%.
Ethyl 6,7-dihydro-6-ethyl-4-phenyl-3-n.propyl-7-oxo-
1H-pyrrolo[2,3-d]pyridazine-2-carboxylate 15b.
Mp ¼ 98–1008C; crystallization solvent ¼ EtOH;
yield ¼ 52%.
1H-NMR (CDCl3), d, ppm: 0.50 (t, 3H, CH2CH2
CH3), 1.35 (m, 8H, NCH2CH3, CH2CH2CH3 and
OCH2CH3), 2.50 (t, 2H, CH2CH2CH3), 4.40 (m,
4H, NCH2CH3 and OCH2CH3), 7.50 (m, 5H, Ar),
10.0 (exch. br. s. 1H, NH).
Anal. found: C, 67.79; H, 6.58; N, 11.91.
C20H23N3O3 requires: C, 67.96; H, 6.57; N, 11.89%.
Ethyl 4-(p-chlorophenyl)-6,7-dihydro-6-ethyl-3-
methyl-7-oxo-1H-pyrrolo[2,3-d]pyridazine-2-carboxylate
15c. Mp ¼ 206–2088C; crystallization solvent ¼
EtOH; yield ¼ 82%.
1H-NMR (CDCl3), d, ppm: 1.40 (m, 6H, NCH2CH3
and OCH2CH3), 2.10 (s, 3H, CCH3), 4.40 (m, 4H,
NCH2CH3 and OCH2CH3), 7.50 (m, 4H, Ar).
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Anal. found: C, 60.23; H, 5.06; N, 11.65.
C18H18N3O3Cl requires: C, 60.08; H, 5.05; N,
11.68%.
Ethyl 6,7-dihydro-3-methyl-7-oxo-4-phenyl-6-n.pro-
pyl-1H-pyrrolo[2,3-d]pyridazine-2-carboxylate 15d.
Mp ¼ 175–1788C; crystallization solvent ¼ EtOH;
yield ¼ 75%.
1H-NMR (CDCl3), d, ppm: 1.00 (t, 3H, NCH2CH2
CH3), 1.45 (t, 3H, OCH2CH3), 1.95 (m, 2H,
NCH2CH2CH3), 2.10 (s, 3H, CCH3), 4.35 (m, 4H,
NCH2CH2CH3 and OCH2CH3), 7.50 (m, 5H, Ar),
11.50 (exch. br. s. 1H, NH).
Anal. found: C, 67.05; H, 6.26; N, 12.37.
C19H21N3O3 requires: C, 67.23; H, 6.25; N, 12.38%.
Ethyl 6,7-dihydro-6-isopropyl-3-methyl-7-oxo-4-phe-
nyl-1H-pyrrolo[2,3-d]pyridazine-2-carboxylate 15e.
Mp ¼ 145–1478C; crystallization solvent ¼ EtOH;
yield ¼ 74%.
1H-NMR (CDCl3), d, ppm: 1.45 (m, 9H, CH(CH3)2
and OCH2CH3), 2.20 (s, 3H, CCH3), 4.45 (q, 2H,
OCH2CH3), 5.50 (m, 1H, CH(CH3)2), 7.60 (m, 5H,
Ar), 11.60 (exch. br. s. 1H, NH).
Anal. found: C, 67.08; H, 6.24; N, 12.40.
C19H21N3O3 requires: C, 67.23; H, 6.25; N, 12.38%.
Ethyl 6-n.butyl-6,7-dihydro-3-methyl-7-oxo-4-phenyl-
1H-pyrrolo[2,3-d]pyridazine-2-carboxylate 15f.
Mp ¼ 136–1388C; crystallization solvent ¼ EtOH;
yield ¼ 64%.
1H-NMR (CDCl3), d, ppm: 0.95 (t, 3H, NCH2
CH2CH2CH3), 1.40 (t, 3H, OCH2CH3), 1.80 (m,
4H, NCH2CH2CH2CH3), 2.10 (s, 3H, CCH3), 4.40
(m, 4H, NCH2CH2CH2CH3 and OCH2CH3), 7.50
(m, 5H, Ar), 10.80 (exch. br.s. 1H, NH).
Anal. found: C, 68.09; H, 6.58; N, 11.92.
C20H23N3O3 requires: C, 67.96; H, 6.57; N, 11.89%.
Pharmacology
Purification of phosphodiesterase 3 (PDE3). Cyclic
nucleotide phosphodiesterases 3 were obtained from
guinea pig ventricular tissue following the procedure
described by Gristwood et al.[36]. Briefly, the tissue
was homogenized in 20 mM Bis-Tris pH 6.5 buffer,
containing 50 mM sodium acetate, 2 mM
benzamidine, 2 mM EDTA, 5 mM b-mercapto-
ethanol and 50mM PMSF using an Ultraturrax
homogenizer. The sample was centrifuged at
40000 £ g for 20 min and the supernatant was
filtered through a 0.22mm filter. The clean sample
was chromatographed on a 1 mL ion-exchange
MONO-Q column equilibrated with the same buffer
using a FPLC system. The column was developed at a
flow rate of 1 mL/min using a linear gradient of
sodium acetate from 50 to 1000 mM in a total
volume of 25 mL. Fractions of 500mL were collected.
The isoenzymes were characterized prior to use in
terms of substrate selectivity and affinity and by the
effect of calcium ions (10mM) plus calmodulin
(1.2mM) and the selective inhibitors Rolipram and
SK& 94120. Active fractions were pooled and kept
frozen at 2208C in the presence of g/L bovine serum
albumin until used.
PDE3 activity determination. Cyclic nucleotide
phosphodiesterase activities were measured using a
two step procedure according to Thompson and
Strada[37]. Inhibition assays were run in duplicate at a
substrate concentration of 0.25mM. Substrate was
cAMP for PDE3. IC50 values were obtained by
nonlinear regression using the program InPlot from
GraphPad Software. Drugs were dissolved in DMSO,
and the effects of this solvent were taken into
consideration in the calculations.
Purification of phosphodiesterase 4 (PDE4). Yeast strains
overexpressing PDE4 were inoculated into 500 ml flasks
with 100 ml YPD (1 g yeast extract, 2 g peptone, 95 ml
H2O, and 5 ml 40% glucose) and grown at 308C under
orbital shaking (150 rpm) for 48 h to ensure reaching
one near OD600 ¼ 2.0. Then cells were harvested by
centrifugation at 1500 rpm for 10 min at 208C. All
supernatants were removed and pellets resuspended in
the appropriate volume of SD (1.7 g yeast nitrogen base
w/o aminoacids and sulphate, 5 g (NH4)2SO4, 30%
galactose, 0.5% adenine sulphate and 0.50 mg/mL L-
lysine-HCl) to obtain an OD600 between 0.4 and 0.6
and then incubated with shaking at 308C until an
OD600 of 2.0 was reached (usually 48 h). Then cells
were centrifuged at 4000 rpm for 20 min at 48C and the
supernatants discarded. Pellets were resuspended in
100 ml of ice-cold sterile water and centrifuged at
4000 rpm for 20 min at 48C. The supernatants were
discarded and the wet weight of pellets was measured
and 1.3 volume/weight of YHB (2 M KCl, 0.5 M
EDTA, 1 M HEPES) supplemented with DTT and
protease inhibitors added and then resuspended.
Another centrifugation at 4000 rpm for 20 min at 48C
was carried out. The supernatants were discarded and
using a spatula the yeast paste was transferred into a
10-mL syringe and yeast “noodles” were made and
placed into a small plastic beaker filled with liquid
nitrogen. The frozen yeast “noodles” can be stored at
2808C until required for extract preparation.
Preparation of whole-cell extract. The yeast “noodles”
were poured into a cooled porcelain mortar filled with
liquid nitrogen and crushed under liquid nitrogen
until the yeast showed a powdery smooth consistency.
Then yeast/liquid nitrogen suspension was poured
into a plastic beaker and the remaining yeast powder
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scraped into the beaker with a spatula. Dialysis buffer
(1.4 volume/ weight), YDB (2 M KCl, 0.5 M EDTA,
1 M HEPES, 100% glycerol, 1 M DTT, 0.25 M
PMSF, 1 mg/mL leupeptin and supplemented with
DTT and protease inhibitors) was then added to
resuspend the yeast powder and then centrifugated at
25000 rpm for 2 h at 48C. The lipid layer was
removed, supernatants recovered and transferred to
dialysis tubing and dialyzed overnight against 500 ml
YDB. Then dialysis supernatants were transferred to
microtubes in small aliquots (100ml) and quick-frozen
and stored at 2808C; The protein concentration was
determined by the method of Bradford with the Bio-
Rad protein assay kit using bovine serum albumin
(BSA) as a standard.
PDE4activity determination. PDE4 activity from various
subtypes (PDE4B1, PDE4A4 and PDE4D3) was
monitored by measuring the hydrolysis of [3H]-AMP
using a PDE-SPA kit (Amersham International) as
reported in the literature[38]. Extracted Enzyme (4mg
of protein) was incubated in “low binding” plates
(Costar 3604) for 60 min at room temperature. The
assay mixture (80mL) contained 15 nM [3H]-cAMP
(1mC/mL) in the assy buffer (50 mM Tris pH 7.5,
8.3 mM MgCl2, 1.7 mM EGTA) and 10mL of test
compound. These compounds were resuspended in
DMSO at a stock concentration of 1 mM. The
compounds were tested at different concentrations
varying fron 10mM to 10 pM to calculate the
ED50.Hydrolysis of [
3H]-cAMP was initiated by
adding 10mL of a solution containing enzyme extract,
and the plate was then incubated under agitation at
room temperature. The reaction was stopped after
60 min (with 10–20% substrate conversion) by
addition of 50mL Phosphodiesterase Scintillation
Proximity Assay (SPA) Beads and the reaction was
incubated for another 20 min. [3H]-AMP, captured by
the SPA beads, was determined by counting the plates
in a Wallac-Microbeta Trilux scintillation counter.
[3H]Rolipram displacement. The binding of [3H]Rolipram
to rat brain membranes was performed according to
Schneider et al.[39] At least six drug concentrations
were assayed in duplicate to generate individual
displacement curves. IC50 values were calculated from
those curves by nonlinear regression using the program
Inplot, from GraphPad Sofware. The effect of drug
vehicle was taken into account in the calculation.
PBMC assay. Human whole blood of healthy donors
was collected in 50 ml Falcon tubes with heparin
(20 units/mL). The isolation of PBMCs by
centrifugation on a Ficoll-Plaque and hypotonic lysis
of remaining red blood cells was performed essentially
as described previously by Gantner and
coworkers[40]. The purity of PBMCs was .90%
and the viability, as measured by trypan blue
exclusion, as .95%. Cells were incubated in 96-well
plates at a density of 2 £ 105 cells/well in a total assay
volume of 200mL (RPMI medium with 2 mM L-Gln,
20 mM Hepes and 10%FBS). A 1mg/mL of LPS
(from Escherichia coli, Sigma, St. Louis, MO) together
with vehicle or test compound was incubated in a bath
at 378C for 24 h. Each drug was evaluated at six
different concentrations in duplicate determinations.
After the 24 h period, the reaction was stopped and
media obtained by centrifugation of PBMCs at
13000 rpm at 48C for 10 min was then subjected to
ELISA (R&D Systems) or kept at 2808C until use.
IC50 values were obtained by non-linear regression
using InPlot, GraphPad. The results were expressed as
the mean IC50 ^ SEM value obtained in 4 indepen-
dent experiments. Results related to this experiment
are reported in Table II.
Results and discussion
All the final compounds were tested for their ability to
inhibit PDE4 (PDE4A, PDE4B and PDE4D) and
PDE3 isoenzymes, as well as for their affinity for
HARBS (Table I).
SAR studies were performed in comparison with the
lead 8 which did not demonstrate subtype selectivity
showing IC50s of 0.11, 0.067 and 0.049mM for
PDE4A, PDE4B and PDE4D respectively, but a
significant selectivity versus HARBS (HARBS/P-
DE4A-C ¼ 20–40) was observed.
Starting from 15a–b, where the methyl group at
position- 3 was elongated with respect to lead 8, an
IC50 in the nanomolar range can be observed, but
unfortunately these agents were completely devoid of
selectivity versus PDE4 subtypes, as well as versus
HARBS. These results clearly indicated that
elongation of the carbon chain at position-3 did not
modify the inhibitory activity but it led to a decrease in
selectivity versus HARBS.
Replacement of the hydrogen at position-1
(compounds 9a–e) by alkyl groups was associated
with significant effects on the selectivity. In fact, even
though 9a–c and 9e showed less potent PDE4
inhibitory activity with respect to the previous
compounds, the selectivity versus HARBS (HARBS/P-
DE4B) was significantly increased, in particular for 9b
(ratio ¼ 67) and 9e (147). This compound was also the
best one in the present series as regards the PDE4
subtypes selectivity profile, being 8 times more potent
for PDE4B, the subtype responsible for the anti-
inflammatory effect (IC50 ¼ 0.32mM) than for PDE4D
(IC50 ¼ 2.5mM), which is generally considered the
subtype responsible for central side-effects.
Introduction of a benzyl group at position-1
(compound 9d) was found very detrimental to activity
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with respect to 9a–c and 9e, where the substituent is a
small alkyl group. This result seems to indicate that
there is a small liphophilic pocket in the catalytic site
of the enzyme which is able to receive linear or
branched low molecular weight alkyls groups.
Introduction of a chlorine in the para position of the
phenyl group (15c) was associated with a moderate
activity for PDE4B and the loss of the selectivity
versus HARBS.
Compounds 15d–f, where the carbon chain at
position-6 was elongated and branched in comparison
to 8, showed a reduced potency towards the three
isoenzymes. Thus in this group of differently 6-
substituted derivatives, a two carbon chain was found
to be optimal.
Finally, all synthesized compounds showed a good
PDE3/PDE4 selectivity profile, as reported in Table I.
In conclusion we synthesized novel PDE4 inhibitors
endowed with IC50 in the nanomolar range. Selectivity
versus HARBS was strongly improved, both in
comparison with Rolipram 1 and our lead 8.
The best profile was found for 9e, which showed a
high potency for PDE4B and a very high selectivity
(147) versus HARBS.
These results suggest that the best arranged groups
around the pyrrolopyridazinone core are an isopropyl
at position-1, an ethoxycarbonyl at position-2 together
with an ethyl group at position-6.
Finally, we evaluated the ability of the most potent
compounds (8 and 15a) and of the less active in this
series (15f) to reduce TNFa production in human
peripheral blood mononuclear cells (PBMC), using
Cilomilast as reference drug (Table II). The obtained
results really demonstrated a correlation between
Table I. Effects of compounds 9 and 15 on PDE4 isoenzymes, PDE3 and displacement of [3H]Rolipram from its binding site (HARBS).
.
Comp. R R1 R2 X PDE4
a,bA A PDE4a,bB PDE4a,bD PDE3a,c [3H]Rola,d
98 Me Me Et H 1.2 ^ 0.3 0.63 ^ 0.12 0.36 ^ 0.05 37.0 ^ 10.0 (20) 1.1 ^ 0.3
9b Et Me Et H 0.71 ^ 0.35 0.63 ^ 0.21 0.28 ^ 0.04 31.0 ^ 15.2 (20) 42.0 ^ 12.4
9c n.Pr Me Et H 2.2 ^ 0.8 0.77 ^ 0.15 1.9 ^ 0.2 26 ^ 9.2 (20) 1.0 ^ 0.2
9d Bn Me Et H 6.3 ^ 1.2 2.4 ^ 0.9 6.1 ^ 1.7 2.0 ^ 0.7 (20) 10.0 ^ 1.9
9e i.Pr Me Et H 1.3 ^ 0.3 0.32 ^ 0.08 2.5 ^ 0.6 33.0 ^ 6.5 (20) 47.0 ^ 15.7
15a H Et Et H 0.079 ^ 0.012 0.093 ^ 0.02 0.022 ^ 0.01 25.0 ^ 8.9 (20) 0.35 ^ 0.08
15b H n.Pr Et H 0.035 ^ 0.013 0.048 ^ 0.011 0.013 ^ 0.007 28.0 ^ 12.3 (20) 0.28 ^ 0.03
15c H Me Et Cl 0.24 ^ 0.08 0.44 ^ 0.10 0.061 ^ 0.024 26.0 ^ 5.7 (20) 0.39 ^ 0.1
15d H Me n.Pr H 3.3 ^ 1.0 1.4 ^ 0.5 1.2 ^ 0.8 9.0 ^ 2.8 (20) 20.1 ^ 3.4
15e H Me i.Pr H 63.7 ^ 20.3(10) 1.6 ^ 0.4 1.4 ^ 0.5 25.0 ^ 4.5 (20) 18.0 ^ 2.7
15f H Me n.Bu H 54.0 ^ 17.8(10) 4.3 ^ 1.3 59 ^ 13.6 (10) 10 ^ 21 (20) 12.0 ^ 5.3
8 H Me Et H 0.11 ^ 0.03 0.067 ^ 0.03 0.049 ^ 0.012 30 ^ 3.3 (20) 2.0 ^ 0.5
Rolipram 0.32e 242.0 0.006
a Data are expressed as IC50 (mM) or inhibition percentage at indicated concentration (mM) (n ¼ 3); b PDE4 was purified and dosed
following the procedure reported in experimental section; c PDE3 were obtained from guinea pig ventricular tissue (ref.36) and dosed
following the procedure of Thompson et al. (ref.37); d [3H]Rolipram tests were performed using brain membranes according to ref. 42.; e Data
related to PDE4 isoenzyme mixture following the procedure of Thompson et al. (ref.37).
Table II. TNFa inhibition values for compounds 8, 15a and 15f.
.
Comp. R1 R2
TNFaa IC50
(mM)
PDE4 Bb IC50
(mM)
8 Me Et 0.20 ^ 0.09 0.067 ^ 0.03
15a Et Et 0.19 ^ 0.1 0.093 ^ 0.02
15f Me n.butyl 45.6 ^ 9.0 4.3 ^ 1.9
Cilomilast 0.09 0.095
a IC50 is the mean of 4 independent experiments.;
b PDE4 was
purified and dosed following the procedure reported in the
experimental section.
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PDE4 inhibitory activity and TNFa release being the
IC50s ¼ 0.198 and 0.192mM for the most active
molecules respectively 4.9mM for compound 15f.
Further studies are in progress to optimize the
profile of the above reported compounds.
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